+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 21 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the effects of dupilumab compared with placebo on airway inflammation, airway resistance, and lung remodeling in people aged 40 to 85 years with Chronic Obstructive Pulmonary Disease COPD. This Phase 4, multinational, randomized, double-blind, placebo-controlled study aims to understand how these changes relate to lung function, exacerbations, and quality of life improvements. Participants will receive subcutaneous injections of either dupilumab or placebo following the study protocol. The treatment period lasts up to 24 weeks within a total study duration of 40 weeks, during which participants will attend nine visits. The study includes detailed lung imaging assessments to measure mucus plugging and airway changes. During the study, participants will undergo evaluations including lung mucus scoring, high-resolution CT scans, and forced oscillation technique tests to monitor airway resistance and reactance. Safety is monitored by recording adverse events up to 36 weeks. The primary outcome is the change in global lung mucus score from baseline to Week 24. Participants will be followed for the full duration to assess treatment effects and safety.

Age: 40Years - 85YearsAll GendersPhase 4
85 locations
A

Actively Recruiting

Researchers are investigating if, for patients with clinically node-positive breast cancer undergoing upfront surgery, treatment with tailored axillary surgery TAS combined with axillary radiotherapy ART is better than axillary lymph node dissection ALND in improving arm-related quality of life QoL and reducing lymphedema two years after treatment. ALND is currently the standard treatment but is associated with major side effects. TAS targets positive lymph nodes more selectively than ALND, potentially causing less harm when combined with ART. The study compares two treatment approaches one group undergoes ALND, the standard surgery removing all lymphatic tissue in the axilla, alongside breast irradiation excluding the axilla the other group receives TAS, which includes sentinel lymph node biopsy and targeted removal of suspicious nodes, combined with breast and axillary radiotherapy ART. All patients receive adjuvant breast irradiation following breast-conserving surgery, with or without axillary radiotherapy depending on their group. The trial follows participants from surgery through post-treatment monitoring. Participants will be assessed from baseline through two years after randomization to monitor changes in arm-related QoL and the occurrence of lymphedema. Researchers will collect quality of life questionnaires and clinical evaluations to measure these outcomes. The study includes randomization into treatment groups and involves regular follow-up to assess long-term effects on arm function and side effects. The overall goal is to determine if TAS plus ART offers improved quality of life compared to ALND.

Age: 18Years +All GendersPhase Not Applicable
55 locations
E

Actively Recruiting

Sensory neuronopathies SN are rare neuropathies characterized by damage to sensory neurons in the dorsal root ganglia, caused by various conditions such as paraneoplastic, autoimmune, toxic, and genetic factors. The functional outlook for patients is generally poor, with many experiencing significant disability. Because there are no reliable biomarkers for SN, clinical scales are used to assess disease severity and treatment response, but currently available scales are not specifically designed or validated for SN. This study is evaluating the use of multiple clinical assessment tools over time to identify the most appropriate scale for tracking disease progression in sensory neuronopathies. Patients will be followed longitudinally with three visits at baseline, 6 months, and 12 months. At each visit, a variety of clinical scales and tests such as mISS, SEARS, CADT, SARA, ONLS, I-RODS, 9-Hole Peg Test, Timed Up and Go test, mRS, Quantified Rydel tuning fork test, Visual Analog Scale, and electroneuromyography ENMG will be conducted. Participants will provide demographic and medical history information at baseline and undergo assessments at each scheduled visit. Researchers will measure changes in clinical scores and neurological function to evaluate these tools effectiveness in monitoring SN. The primary outcomes include the Clinical Global Impression of Change and Patient Global Impression of Change at 6 and 12 months. The study lasts 12 months with comprehensive follow-up and safety monitoring to better understand disease progression.

Age: 18Years +All GendersPhase Not Applicable
19 locations
C

Actively Recruiting

Researchers are investigating the best approach to treat low-risk patients with isolated subsegmental pulmonary embolism SSPE, a type of blood clot in small lung arteries. The study aims to determine whether monitoring patients without anticoagulation is as safe and effective as giving anticoagulant medication. This is important because many patients currently receive anticoagulants that carry a risk of bleeding, but it is unclear if all patients with isolated SSPE need this treatment. Patients in the trial are randomly assigned to one of two groups. One group receives the anticoagulant drug rivaroxaban, starting with 15 mg twice daily for 21 days, then 20 mg once daily for a total of 90 days. The other group receives a placebo matching the same schedule. The trial compares clinical surveillance without anticoagulation to anticoagulation treatment to assess safety and effectiveness. Participants will be followed for 90 days after randomization to monitor for recurrent venous thromboembolism, significant bleeding events, and overall survival. Researchers will track these outcomes through clinical assessments and safety monitoring. This study is designed to evaluate if careful monitoring alone is a safe alternative to anticoagulation in selected patients with isolated SSPE, potentially reducing bleeding risks from treatment.

Age: 18Years +All GendersPhase 4
40 locations
O

Actively Recruiting

Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.

Age: 18Years +All Genders
216 locations
E

Actively Recruiting

Researchers are collecting real-world data from cancer patients who receive radiotherapy to better understand the role of radiation oncology within a multidisciplinary treatment approach. This open-ended, prospective, non-interventional study aims to support radiotherapy research by observing patients over time without providing therapeutic interventions. The study includes patients with various cancer types who are planned to receive radiotherapy. Participants include patients treated with radical radiotherapy for oligometastatic disease as well as those receiving high-dose re-irradiation. The study is organized into multiple cohorts, such as OligoCare and ReCare, based on the type of radiotherapy treatment. Since it is an observational study, no experimental treatments or placebos are given. During the study, researchers will collect data on patient outcomes including disease-free survival, loco-regional control, distant metastasis-free survival, overall survival, and any adverse events related to radiotherapy over a period of five years. The main measure is the number of patients treated with radiotherapy enrolled in the program. Participants will have their health and treatment effects monitored regularly throughout this timeframe to provide valuable information about radiotherapy outcomes in real-world clinical settings.

Age: 12Years +All Genders
77 locations
E

Actively Recruiting

This research aims to evaluate the effectiveness of early minimally invasive image-guided hematoma evacuation combined with best medical treatment BMT compared to BMT alone in patients with spontaneous supratentorial intracerebral hemorrhage SSICH. SSICH is a serious form of stroke with poor outcomes and limited treatment improvements from current standard care or traditional surgery. This open-labeled, randomized controlled trial seeks to determine if early endoscopic surgery within 24 hours of bleeding onset can improve functional outcomes at 6 months. Participants are randomly assigned to one of two groups. The intervention group receives BMT plus early minimally invasive endoscopic hematoma evacuation performed within 6 to 24 hours after symptom onset, using advanced imaging and neuro-navigation techniques to guide the surgical procedure. The control group receives best medical treatment alone, which includes strict blood pressure control, seizure prevention, intensive care monitoring, and other guideline-based supportive care. The study involves six visits, with four during hospital stay and two follow-ups as part of routine care. During each visit, assessments include the Glasgow Coma Scale GCS, modified Rankin Scale mRS, and National Institute of Health Stroke Scale NIHSS. Three visits involve CT scans and blood sampling, while other visits assess patient satisfaction, cognition, and quality of life. The primary outcome is functional status measured by mRS at 6 months. Secondary outcomes include mortality rates, cognitive changes, neurological deficits, quality of life, and time spent in intensive care. The trial runs until December 2029 and was designed with patient and public input.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
10 locations
E

Actively Recruiting

This research evaluates the safety and performance of the Castor and Cratos Branched Aortic Stent Graft Systems for treating thoracic aortic diseases in the descending aorta. The study collects data from around 100 patients in European hospitals to understand how these devices perform in everyday medical practice over short, medium, and long terms. Participants receive treatment with either the Castor or Cratos stent grafts designed to support the aortic arch and left subclavian artery. The study includes both retrospective and prospective data collection, following patients according to each hospitals standard care practices after device implantation. Throughout the study, researchers monitor participants health using measures such as 30-day mortality, technical success within 24 hours, clinical success up to 5 years, rates of complications like endoleaks, branch occlusion, strokes, and reinterventions. Follow-up assessments occur at 30 days, 6 months, and annually up to 5 years, with the entire study lasting until 2033.

Age: 18Years +All Genders
4 locations
C

Actively Recruiting

This trial focuses on adults with Clostridioides difficile infection CDI, including those experiencing their first episode with risk factors for recurrence or their first recurrence. Researchers aim to compare the effectiveness of fecal microbiota transplantation FMT combined with standard antibiotic treatment against standard antibiotic treatment alone, to prevent further CDI recurrences. This Phase III, randomized, open-label trial addresses an important challenge since recurrent CDI causes significant health problems and reduced quality of life. Participants are randomly assigned to one of two groups. One group receives standard oral antibiotics vancomycin or fidaxomicin for 10 days, followed by FMT capsules administered over two consecutive days patients with severe CDI receive a second FMT over the next two days. The other group continues with the standard antibiotic treatment alone for 10 days. The FMT capsules are prepared from healthy donors and given orally after a brief antibiotic pause. Throughout the study, participants are monitored for sustained clinical cure assessed 8 weeks after treatment completion, with follow-up lasting 12 months. Researchers evaluate treatment failure, new CDI episodes, long-term cure rates, recurrence-free survival, overall survival, and health status using standardized questionnaires. The study aims to gather comprehensive data on the safety and efficacy of FMT combined with standard antibiotics in preventing CDI recurrence.

Age: 18Years +All GendersPhase 3
8 locations
H

Actively Recruiting

This trial focuses on children with focal cerebral arteriopathy FCA, a rare but serious condition that causes stroke in childhood. FCA is an inflammatory disease of the blood vessels in the brain triggered by infection. Researchers aim to find out if treating children with high dose steroids plus aspirin leads to better and faster recovery, improved clinical outcomes, and fewer stroke recurrences compared to treatment with aspirin alone. This is a phase 3, randomized controlled study conducted across multiple international centers. Participants will be randomly assigned to one of two groups one group will receive standard care including aspirin plus high dose intravenous methylprednisolone followed by oral prednisolone tapering, while the other group will receive standard care including aspirin without steroids. Steroid treatment is given intravenously for 3 days at 30 mgkgday maximum 1000 mgday, followed by oral prednisolone for 4 weeks with a tapering dose schedule. Treatment begins within 48 hours of diagnosis and no later than 96 hours after stroke onset. Children will be monitored at 1, 3, 6, and 12 months after treatment begins. Evaluations include neurological exams, MRI and MRA imaging at 1, 3 if available, and 6 months, and various outcome assessments such as stroke severity scores, functional measures, cognitive tests, and quality of life questionnaires. Researchers will track recovery, stroke recurrence, and vessel changes to assess treatment effects and safety over the study duration of 48 months.

Age: 6Months - 17YearsAll GendersPhase 3
35 locations

1-10 of 21

1